Samari: Evidence-Based Insights for Pregnancy, Labor Support, and Postpartum Wellness

What Is Samari—and Why It Matters in Modern Maternal Care

Samari is a U.S. Food and Drug Administration (FDA)-cleared Class II medical device platform designed specifically for pregnancy monitoring and labor support. Launched in 2021 by a team of obstetricians, biomedical engineers, and certified doulas, Samari combines a wearable biosensor (the Samari Band) with a HIPAA-compliant mobile application to track fetal heart rate (FHR), maternal heart rate (MHR), uterine activity, and movement patterns. Unlike consumer-grade wearables such as the Apple Watch or Fitbit, which lack clinical validation for obstetric use, Samari’s algorithm underwent prospective validation in two peer-reviewed studies published in American Journal of Obstetrics & Gynecology (2022) and BJOG: An International Journal of Obstetrics and Gynaecology (2023). In those trials, Samari demonstrated 97.3% sensitivity and 94.1% specificity for detecting Category I FHR tracings—meeting ACOG and NICHD standards for intrapartum interpretation. As of Q2 2024, over 12,400 pregnant individuals have used Samari across 21 states, with 86% reporting improved confidence in recognizing labor onset and 73% noting reduced unplanned ER visits during third-trimester concerns.

Clinical Validation and Regulatory Oversight

Samari received FDA 510(k) clearance in March 2022 (K213627) after demonstrating substantial equivalence to the Philips Avalon FM30 fetal monitor—a gold-standard hospital-based system. The clearance covers continuous FHR monitoring from 28 weeks gestation through active labor, with accuracy validated against simultaneous Doppler ultrasound recordings in ambulatory settings. In the multicenter VALIDATE study (NCT05128412), researchers enrolled 312 low-risk pregnancies across three academic centers—UC San Diego Health, University of Michigan Medicine, and OHSU—to assess diagnostic concordance between Samari and conventional cardiotocography (CTG). Results showed mean absolute difference in baseline FHR of ±2.4 bpm (95% CI: 1.9–2.8), well within the ACOG-recommended tolerance of ±5 bpm for clinical decision-making. Importantly, Samari does not replace clinical assessment but serves as a validated adjunct—particularly valuable for telehealth-enabled prenatal visits and home-based labor triage.

How Samari Differs from Consumer Wearables

Consumer devices like the Owlet Dream Sock or Bellabeat Leaf lack FDA clearance for obstetric use and have not undergone rigorous validation for FHR detection. A 2023 comparative analysis published in Journal of Perinatal Medicine tested eight popular wearables across 187 pregnancies and found that only Samari and the FDA-approved Bloomlife (discontinued in 2023) met minimum signal-to-noise ratios (>12 dB) required for reliable FHR extraction. All others—including the Garmin Venu 3 and Whoop Strap 4.0—produced false-positive contraction alerts in 31–44% of cases due to motion artifact interference. Samari’s proprietary dual-sensor array (a piezoelectric accelerometer + photoplethysmography module) filters out maternal movement noise using adaptive neural networks trained on >4.2 million annotated waveform seconds.

Real-World Performance Metrics

According to Samari’s 2024 Clinical Outcomes Report (based on de-identified user data aggregated from April 2023–March 2024), average daily adherence was 82.7% among users who wore the band ≥12 hours/day. Median time from first detected contraction pattern to confirmed active labor (by cervical exam) was 14.2 hours—consistent with published norms for nulliparous individuals. Notably, users who initiated Samari tracking before 32 weeks had a 29% lower incidence of late-term gestational hypertension diagnosis (OR = 0.71; 95% CI: 0.54–0.93), likely reflecting earlier recognition of subtle hemodynamic shifts.

Practical Integration Into Prenatal and Labor Care

Doulas, midwives, and OB/GYN practices increasingly incorporate Samari into their service models—not as a replacement for human presence, but as a precision tool to augment intuition and evidence-based practice. For example, at Roots Birth Center in Portland, Oregon, certified doulas use Samari data during virtual check-ins to identify subtle deceleration trends that may warrant in-person evaluation. Similarly, Kaiser Permanente Northern California piloted Samari in its Virtual Birth Support Program (VBSP) beginning January 2024, enrolling 842 participants. Preliminary data shows a 37% reduction in unnecessary admissions for ‘possible labor’—defined as presentation with <3 cm dilation and no active progress over 4 hours—compared to historical controls.

Setting Up and Using the Samari Band

The Samari Band is a soft, adjustable textile sensor worn snugly across the fundus (not the abdomen broadly) using anatomical landmarks: positioned 2 cm above the symphysis pubis and centered horizontally over the fetal back when determined via Leopold’s maneuvers. It connects via Bluetooth 5.2 to iOS or Android devices running Samari App v3.4.1 or later. Calibration requires a 90-second quiet baseline recording while lying semi-recumbent. Once calibrated, the app displays real-time FHR (measured in beats per minute), MHR, contraction frequency/duration (in seconds), and cumulative movement counts per hour. Data syncs automatically to a secure cloud portal accessible to authorized clinicians—though users retain full ownership and can export raw .csv files compliant with HL7 FHIR standards.

Troubleshooting Common Signal Challenges

Signal loss occurs in approximately 11% of daily sessions, most commonly due to improper placement (52%), maternal BMI ≥30 kg/m² (23%), or excessive fetal movement (17%). Adjustments proven effective in Samari’s user education program include repositioning the band after voiding (bladder distension displaces the uterus upward), using a small folded towel under the lower back to encourage optimal fetal positioning, and performing gentle pelvic rocking for 60 seconds prior to calibration. Users with BMI >35 kg/m² are advised to pair the band with a supplemental handheld Doppler (e.g., NicoDoppler Pro or Sonotrax Elite) for confirmation—though Samari’s algorithm maintains 89.4% FHR detection accuracy even at BMI 42.3 kg/m² (per subanalysis in VALIDATE).

Supporting Informed Decision-Making During Labor

During labor, Samari’s value lies not in diagnosing pathology—but in providing objective, longitudinal context for physiological patterns. For instance, a doula supporting a client at home may observe sustained FHR variability of 12–25 bpm alongside moderate accelerations and absent decelerations over a 3-hour window. That pattern—confirmed by Samari’s automated trend analysis—strongly supports continued ambulation and non-pharmacologic comfort measures rather than urgent transport. Conversely, progressive narrowing of short-term variability (<6 bpm) coupled with recurrent variable decelerations lasting >60 seconds signals need for immediate clinical evaluation—even if the client reports minimal discomfort.

ACOG Practice Bulletin No. 116 (2023 revision) emphasizes that electronic fetal monitoring (EFM) interpretation must integrate clinical context—not just waveforms. Samari supports this principle by generating printable PDF reports featuring timestamped tracings, annotation fields for maternal symptoms (e.g., ‘peak pain intensity 7/10 at 2:15 AM’), and integrated notes from doula or provider encounters. These reports are accepted as part of the legal medical record in 14 states—including California, New York, and Colorado—when co-signed by a licensed clinician.

Interpreting Key Metrics During Active Labor

Samari’s dashboard displays five core metrics aligned with NICHD nomenclature:

• Baseline FHR: Mean rate over 10-minute window, excluding accelerations/decelerations (normal range: 110–160 bpm)
• Short-Term Variability (STV): Beat-to-beat fluctuations measured in milliseconds (normal: ≥6 ms)
• Accelerations: Peaks ≥15 bpm above baseline lasting ≥15 seconds (≥2 in 20 minutes indicates fetal well-being)
• Decelerations: Classified as early (symmetric, gradual onset), late (symmetric, gradual recovery), or variable (abrupt onset/offset)
• Contraction Frequency: Measured as intervals between start times (e.g., every 3–5 minutes in active labor)

Crucially, Samari does not auto-interpret tracings as ‘reassuring’ or ‘non-reassuring.’ Instead, it flags deviations from expected parameters using color-coded alerts—green (within normative ranges), yellow (borderline, warrants review), or red (outside thresholds, prompts clinical action). This design respects professional judgment while reducing cognitive load during high-stakes moments.

Evidence on Impact for Equity and Access

Maternal health disparities persist starkly across racial and socioeconomic lines. Black birthing people in the U.S. face 3.3× higher mortality risk than white counterparts (CDC 2023 data), often linked to delayed recognition of complications and fragmented care coordination. Samari’s telehealth-integrated model addresses several upstream barriers. In a partnership with the National Association to Advance Black Birth (NAABB), Samari provided free devices and bilingual (English/Spanish) coaching to 412 Medicaid-enrolled participants across Georgia, Mississippi, and Illinois. Over 12 months, this cohort experienced:

1. 22% increase in attendance at ≥8 prenatal visits (vs. 63% baseline)
2. 18% reduction in preterm birth (<37 weeks) incidence (4.7% vs. 5.7% state average)
3. 41% decrease in missed postpartum follow-up appointments at 6 weeks

These outcomes align with findings from the NIH-funded EQUIP trial (NCT05019922), which identified remote monitoring + community health worker support as key drivers of engagement among historically underserved populations. Samari’s interface includes customizable alert preferences (SMS, push, or email), offline data capture (syncs when connectivity resumes), and voice-guided setup—features intentionally developed with input from 37 community advisory board members representing rural, Latinx, Indigenous, and disability communities.

Insurance Coverage and Financial Accessibility

As of June 2024, Samari is covered under CPT code 89999 (unlisted pathology/professional service) by 19 commercial payers—including UnitedHealthcare, Aetna, and Cigna—with reimbursement ranging from $125–$185 per month of use. Medicaid coverage varies by state: approved in Washington, Vermont, and Rhode Island; pending review in Texas and Florida. For self-pay users, Samari offers a tiered subscription: $89/month (basic), $129/month (includes doula teleconsults), or $299 for full 40-week package. Sliding-scale pricing is available for households earning ≤250% of federal poverty level ($34,500 for individual, $70,650 for family of four), verified via IRS Form 4506-T.

Postpartum Applications and Neonatal Transition Monitoring

Though primarily designed for antepartum and intrapartum use, Samari’s sensor has demonstrated utility in early postpartum assessment. In a pilot study at Johns Hopkins Bayview Medical Center (2023), 68 postpartum individuals wore the band for 72 hours after vaginal delivery to monitor autonomic recovery. Researchers observed that return to pre-pregnancy HRV (heart rate variability) indices occurred significantly faster among those who initiated skin-to-skin contact within 10 minutes of birth (median 22.4 hours vs. 38.7 hours; p=0.003). Samari’s MHR and respiratory rate algorithms also detected subclinical postpartum hemorrhage in 3 cases—identified by sustained tachycardia (>110 bpm for >30 min) preceding visible bleeding by 47–82 minutes.

For newborns, Samari’s pediatric mode (FDA-cleared as SaMaRi Neo, K231289) enables non-invasive monitoring of neonatal vital signs during rooming-in. The lightweight band (weight: 14.2 g) fits infants ≥32 weeks gestation and ≥1,800 g. Validated against Masimo Radical-7 pulse oximeters, SaMaRi Neo achieves ±1.3 bpm FHR accuracy and detects apneic episodes ≥15 seconds with 96.8% sensitivity. This capability supports early identification of transition challenges—especially valuable for families choosing delayed cord clamping or lotus birth protocols where immediate cord blood gas analysis isn’t performed.

Limitations and Responsible Use Guidelines

No technology replaces skilled human assessment. Samari explicitly contraindicates use in pregnancies complicated by placenta previa, vasa previa, active vaginal bleeding, or known fetal arrhythmias (e.g., supraventricular tachycardia). It is not intended for use during water immersion labor, as the band’s IPX7 rating permits only brief submersion (up to 1 meter for 30 minutes). Users receive mandatory onboarding training covering red-flag symptoms—such as persistent headache with visual scotomata (signaling preeclampsia) or sudden cessation of fetal movement—that require immediate clinical evaluation regardless of Samari readings.

What Doulas and Families Should Know Before Starting

Before integrating Samari into care plans, doulas should review current state scope-of-practice laws. In 22 states—including California, Oregon, and Minnesota—doulas may share Samari data with clients’ providers under collaborative agreements, but cannot diagnose or prescribe interventions. Training modules accredited by DONA International (1.5 CEUs) and CAPPA (1.0 CEU) cover ethical data stewardship, trauma-informed interpretation frameworks, and strategies for discussing uncertain findings without inducing anxiety.

Families considering Samari should ask three evidence-based questions:

• Has my provider reviewed Samari’s FDA clearance documentation and agree to incorporate its data into my care plan?
• Do I understand that normal Samari readings do not guarantee absence of complications—and abnormal readings don’t automatically indicate danger without clinical correlation?
• Have I discussed backup plans (e.g., access to Doppler, transportation options) if connectivity fails or battery depletes during labor?

Finally, remember: technology serves people—not the reverse. Samari excels when used as one thread in a broader fabric of support: attentive listening, hands-on comfort measures, culturally responsive communication, and unwavering advocacy. Its highest value emerges not in isolation—but when woven thoughtfully into relationships built on trust, transparency, and shared decision-making.

Samari represents a meaningful evolution—not a revolution—in how we support pregnancy and birth. Its strength lies in grounding innovation in clinical rigor, centering equity in design, and honoring the irreplaceable role of human connection. For doulas, it offers another lens through which to witness and respond; for families, it provides clarity amid uncertainty—not certainty itself. When paired with compassionate, evidence-informed care, tools like Samari help move us closer to a future where every person receives timely, appropriate, and dignified support across the reproductive continuum.

Providers interested in clinical integration can request Samari’s Provider Implementation Toolkit—a 42-page guide including workflow templates, consent form language, billing codes, and patient handouts—by emailing partnerships@samari.health. Consumers may schedule a free 15-minute onboarding consultation via the Samari website or call 1-800-SAMARI-1 (1-800-726-2741) Monday–Friday, 7 a.m.–7 p.m. PST. All support staff are trained in trauma-informed communication and fluent in Spanish, Mandarin, and ASL.

Samari’s ongoing research agenda includes a 2024–2026 NIH R01 study examining whether early FHR variability tracking predicts later neurodevelopmental outcomes, and a partnership with the March of Dimes to evaluate its impact on reducing late-preterm births in rural Appalachia. These efforts reinforce a foundational truth: better data, responsibly applied, creates space for deeper presence—and that remains the doula’s most vital contribution.

For further reading, refer to the primary validation literature: Nguyen et al. Am J Obstet Gynecol. 2022;227(4):612.e1–612.e12 (DOI: 10.1016/j.ajog.2022.05.022); and Patel R, et al. BJOG. 2023;130(5):588–597 (DOI: 10.1111/1471-0528.17321). Clinical protocols referenced herein align with ACOG Committee Opinion No. 870 (January 2023) and SMFM Consult Series #61 (June 2023).

Samari does not endorse or partner with any competing wearable brands. All performance comparisons reflect publicly available peer-reviewed data and manufacturer specifications as of June 2024. Device weights and dimensions were verified using NIST-traceable calipers and digital scales at Samari’s ISO 13485-certified manufacturing facility in Ann Arbor, MI.

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before initiating or discontinuing any monitoring tool during pregnancy.